Triiodothyronine and Thyroxine in Hyperthyroidism

COMPARISON OF THE ACUTE CHANGES DURING THERAPY WITH ANTITHYROID AGENTS

J. ABUD and P. R. LARSEN

From the Division of Endocrinology and Metabolism, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15261

ABSTRACT In 66 untreated patients with hyperthyroidism, serum triiodothyronine (T₃) and thyroxine (T₄) concentrations were measured by immunoassay. The mean T₃ level was 478±28 ng/100 ml (all values mean±SEM) and the T₄ was 20.6±0.6 μg/100 ml. The serum T₄/T₃ ratio by weight was 48±2 as opposed to a value of 71±3 in euthyroid adults. There was a significant inverse correlation of the T₄/T₃ ratios with serum T₃ (r = 0.77; P < 0.01) but not with serum T₄ (r = 0.21). These results suggested that relative overproduction of T₃ is consistently present in patients with hyperthyroidism.

To examine the acute effects of various antithyroid agents on serum T₃ and T₄ concentrations, iodide, propylthiouracil (PTU), and methylmercaptoimidazole (MMI) were given alone to nine patients, and serial T₃ and T₄ measurements were made. There was an acute decrease in serum T₃ over the first 5 days in the three iodide and three PTU-treated patients which was greater than that seen in the MMI group. This suggested that PTU and MMI had different effects on T₃ production.

To compare the effects of PTU and MMI under conditions in which thyroidal hormone release was minimized, these drugs were given in combination with iodide. The mean daily dosage of PTU was 827 (n = 11) and of MMI was 88 (n = 8). In the PTU + iodide group, the initial serum T₃ concentration was 586±61 ng/100 ml and decreased significantly to 326±41 on day 1 and to 248±21 and 231±20 on days 2 and 3, respectively, and did not change further on days 4 and 5. In the MMI + iodide group, basal serum T₃ was 645±90 ng/100 ml and decreased to 568±81, 452±73, and 344±51 on days 1, 2, and 3, respectively, and did not change thereafter. While the initial T₃ concentrations in serum were not different in the PTU and MMI groups, the T₃ concentrations in the PTU patients were significantly lower on days 1 and 2 and during the apparent plateau period on days 3–5. Serum T₄ concentrations decreased gradually in both groups, from 23.9±2.0 μg/100 ml, initially, to 17.5±1.6 on day 5 in the PTU group and from 22.0±2.6 to 14.6±2.0 in the MMI-treated patients. The T₄ values were not significantly different at any time. These changes resulted in increases in the serum T₄/T₃ ratios in both groups, but these ratios were substantially higher in the patients treated with PTU + iodide. The initial serum T₄/T₃ ratio was 43±3 and increased to 74±7 and 88±7 on days 1 and 2 in the PTU group, reaching a plateau value of 91±7 during days 3–5. Comparable values for MMI-treated patients were 35±2, 42±3, 52±6, and 54±3 during the plateau period.

Previous investigations have shown that PTU inhibits T₃ deiodination in hyperthyroid patients and decreases T₃ production from T₄ in animals. The greater acute decrease in serum T₄ and the higher serum T₄/T₃ ratios in the PTU-treated patients seems best explained by an inhibition of peripheral T₃ production by this agent. This conclusion is further supported by a direct relationship between the T₄/T₃ ratio on days 3–5 and the dose of PTU administered. These results further suggest that both thyroidal and extrathyroidal pathways contribute substantially to the apparent overproduction of T₃ in hyperthyroidism.

INTRODUCTION

There is increasing evidence that triiodothyronine (T₃) plays an important role in normal thyroid physiology. It has even been speculated that thyroxine (T₄) exerts
little metabolic effect unless it is deiodinated to \( T_3 \) in the peripheral tissues (1). Although thyrotoxicosis is most commonly associated with increases in circulating levels of both \( T_4 \) and \( T_3 \), review of the available studies indicates that the concentration of the latter is generally elevated to a greater extent than is \( T_4 \) (2). The mechanism of this disproportionate increase in \( T_3 \) and its metabolic implications are not clearly understood. Since serum \( T_3 \) elevations appear to be consistently present in hyperthyroid patients and since \( T_3 \) may be the active form of thyroid hormone, it was of interest to document the changes in its concentration during therapy with commonly used antithyroid agents. In addition, the halflife of \( T_3 \) is short so that inhibition of \( T_3 \) production should be rapidly reflected in decreases in serum hormone concentrations. Preliminary studies from this laboratory have indicated that substantial changes in circulating \( T_3 \) may occur within 24 h of initiation of therapy (3). The studies reported below were performed to compare changes in \( T_4 \) and \( T_3 \) levels during the early time periods after starting treatment with propylthiouracil (PTU) or methimercaptopimidazole (MMI) alone or in combination with iodide.

**METHODS**

The patients employed in this study were clinically and chemically hyperthyroid. All were hospitalized at the University of Pittsburgh Health Center Hospitals. In 66 patients serum \( T_4 \) and \( T_3 \) concentrations were measured before treatment by radioimmunoassay techniques described previously (4, 5). 28 patients with Graves' Disease were studied during therapy while inpatients either in the Clinical Research Unit or the medical wards of the Presbyterian-University Hospital or V. A. Hospital. These patients were given various drug regimens on a random basis. All drugs were administered orally every 6 or 8 h with one exception where NaI was administered intravenously. Collection of blood samples was performed at two different times before therapy and every 12-24 h after initiation of therapy and for 5 days in most cases. The samples were allowed to clot, and the serum was separated and frozen until assayed. Serial determinations of \( T_4 \) and \( T_3 \) were performed in duplicate, at two dilutions, in the same assay for each patient, and at least in two different assays. \( T_4/T_3 \) ratios were calculated on a weight basis. The study groups were as follows:

(a) PTU, MMI, or iodide alone. Nine patients were studied during therapy with either PTU (three), MMI (three), or iodide alone (three). Mean daily doses were 817 mg (range 750-900 mg) for PTU, 80 mg (range 60-90) for MMI, and 15 gtt of saturated solution of potassium iodide (SSKI) in the three patients receiving iodide.

(b) PTU or MMI in combination with iodide. 19 patients were studied in this group. 11 received PTU + iodide and eight received MMI + iodide. Mean daily doses were 227 mg (range 300-1,600 mg) for the PTU group and 88 mg (range 75-120) for the MMI group. Iodides were usually given as SSKI, 5 gtt every 8 h.

**RESULTS**

*Serum \( T_4 \), \( T_3 \), and \( T_4/T_3 \) ratios in untreated thyrotoxicosis.* The mean \( T_4 \) and \( T_3 \) concentrations in the serum of 66 untreated hyperthyroid patients were 478±28 ng/100 ml and 20.6±0.6 \( \mu \)g/100 ml.

In virtually all patients the circulating levels of these two hormones are increased, but greater increases in \( T_4 \) were apparent in most. As a result, in all but two of the subjects studied the \( T_4/T_3 \) ratio in serum is lower than the mean value of 71±3 which we have observed in euthyroid subjects (2). The mean \( T_4/T_3 \) ratio in the hyperthyroid subjects was 48±2. When the \( T_4/T_3 \) ratios are plotted against the concentrations of either \( T_4 \) or \( T_3 \) in the same specimen, there is a significant inverse correlation between the \( T_4/T_3 \) ratios and the concentration of \( T_3 \) (Fig. 1). In contrast, there is no significant correlation between \( T_4/T_3 \) ratios and \( T_3 \). These findings indicate that decreases in circulating \( T_4 \) in hyperthyroidism are not accompanied by proportionately large increases in serum \( T_3 \).

*Acute changes in serum \( T_4 \), \( T_3 \), and \( T_4/T_3 \) ratios in hyperthyroid patients treated with iodide, MMI, or PTU*
alone. In Fig. 2 are shown results of preliminary studies performed to explore the quantitative changes in $T_3$ and $T_4$ in patients receiving these agents. With iodide therapy, there is an acute decrease in circulating $T_4$ to 50% of the initial level by day 4. $T_3$ values are also significantly lower on day 4, but the decrease is only to 70% of control levels. The mean $T_4/T_3$ ratio at 4 days was 58 compared to 42 initially. The more rapid decrease in serum $T_3$ than in serum $T_4$ was anticipated following inhibition of thyroidal secretion since the half-life of $T_3$ is considerably shorter than $T_4$. Therefore, the increase in the $T_4/T_3$ is consistent with an acute inhibition of thyroidal secretion which has been previously demonstrated to occur during iodide administration to hyperthyroid subjects (6, 7). The failure of serum $T_3$ to fall to normal levels is presumably a reflection of both incomplete inhibition of thyroidal release as well as persistence of $T_3$ production from $T_4$ in the periphery.

With MMI therapy the pattern of changes varies. In one patient there is an acute decrease in serum $T_4$ to about 55% of the initial level by day 3 and an associated decrease in serum $T_3$ of less magnitude. In the other two patients, a slight decrease in $T_3$ levels to about 70% of the initial level was seen in one, no change in $T_3$ in the other, and neither showed significant changes in $T_4$. The heterogeneity of the response pattern of these patients to MMI is not surprising since this drug inhibits synthesis of thyroid hormones but has no effect on the release of previously formed hormonal stores. Since these may vary quantitatively in different individuals with hyperthyroidism, early changes in serum $T_3$ and $T_4$ concentrations during treatment with MMI would be expected to vary accordingly.

During treatment with PTU the decreases in serum $T_3$ concentrations were more uniform. Mean serum $T_3$ concentrations decreased significantly to 50% of the initial level on day 3. The decreases in serum $T_3$ occurred in the absence of significant decreases in serum $T_4$ and are reflected in marked acute increases in the $T_4/T_3$ ratios. The uniformity of the response to PTU and the magnitude of the decrease in serum $T_3$ concentrations suggested an effect different from that of MMI.

Previous studies have indicated that PTU inhibits peripheral deiodination of $T_3$ in hyperthyroid subjects (8, 9). Since this effect of PTU is associated with inhibition of $T_3$ production in animals, it seemed possible
that a similar mechanism could account for the acute decreases in serum T₃ seen in these patients (10). Therefore, we examined this possibility under conditions where the qualitative and quantitative contributions of secretion of preformed hormones was minimized by the concomitant administration of iodide. MMI, which has not been shown to have a peripheral effect in man, provided a control for the antithyroid effect of PTU (11, 12).

**Acute changes in serum T₃ and T₄ in hyperthyroid patients treated with PTU or MMI combined with iodide.** The effect of treatment of hyperthyroid patients with the combination of PTU or MMI with iodide is shown in Fig. 3, and the individual data are presented in Table I. Mean initial serum T₃ and T₄ concentrations were similar in both groups. Statistically significant differences in serum T₃ concentrations were observed on days 1 and 2, with greater decreases in serum T₃ obtained with PTU + iodide. In this group, mean initial T₃ was 586 ng/100 ml and fell to 326 in the first 24 h of treatment (P < 0.001). A decrease of similar magnitude was not observed until day 3 in the MMI + iodide group. A further decrease in T₃ concentration was observed in the PTU + iodide group on day 2, and during days 3–5 the T₃ levels were significantly lower than the initial levels but were not significantly different from each other. A similar plateau was observed on days 3–5 in the MMI + iodide group. The mean serum T₃ concentration during that period was 364±57 ng/100 ml for MMI + iodide and 225±18 for PTU + iodide (P < 0.025 for days 3–5 combined).

In contrast to serum T₃, T₄ concentrations in serum decreased gradually in both groups. The similar rates of fall in both groups resulted in mean values that were not significantly different at any point during the study period. The apparent half-time for the decrease in serum T₄ was 10 days in the PTU + iodide group and 8 days in the MMI + iodide group as determined by least squares analysis of the regression curves.

**Comparison of the acute changes in the serum T₄/T₃ ratios.** The simultaneous changes in serum T₃ and T₄ resulted in marked acute increases in the T₄/T₃ ratios in the patients receiving PTU + iodide (Fig. 4). In this group, there was an increase from 43±3 initially to 74±7 and 88±7 on days 1 and 2, respectively, after which an apparent mean plateau value of 91±7 was observed on days 3–5. In the MMI + iodide group, the mean initial T₄/T₃ ratio of 35±2 was not significantly different from the initial value in the PTU + iodide group. The T₄/T₃ ratios of 42±3 and 45±3 on days 1 and 2 and the plateau

![Figure 3](image1.png)

**Figure 3** Serum T₃ and T₄ in hyperthyroid subjects treated with PTU or MMI in combination with iodide. Values are the mean±SEM of 11 subjects for PTU + iodide and eight subjects for MMI + iodide. The line joining the T₄ values was determined by least squares analysis of the regression curve.

![Figure 4](image2.png)

**Figure 4** Serum T₄/T₃ ratios in hyperthyroid subjects during treatment with PTU or MMI in combination with iodide. Values represented are the mean±SEM.

![Figure 5](image3.png)

**Figure 5** Correlation between the mean serum T₄/T₃ ratios on days 3–5 of therapy in individual patients and the dose of PTU or MMI. Linear regression was determined by least squares analysis.
Table I

*T*<sub>3</sub> and *T*<sub>4</sub> during Treatment of Hyperthyroidism with PTU or MMI in Combination with Iodide

<table>
<thead>
<tr>
<th>Subject</th>
<th>Day of therapy</th>
<th>PTU + Iodide</th>
<th>MMI + Iodide</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>0</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td>ng/100 ml</td>
<td>μg/100 ml</td>
<td>mg*</td>
</tr>
<tr>
<td>F. B.</td>
<td>935</td>
<td>635</td>
<td>239</td>
</tr>
<tr>
<td>W. K.</td>
<td>913</td>
<td>294</td>
<td>268</td>
</tr>
<tr>
<td>C. H.</td>
<td>700</td>
<td>512</td>
<td>—</td>
</tr>
<tr>
<td>B. R.</td>
<td>659</td>
<td>211</td>
<td>194</td>
</tr>
<tr>
<td>M. F.</td>
<td>584</td>
<td>309</td>
<td>237</td>
</tr>
<tr>
<td>K. P.</td>
<td>570</td>
<td>326</td>
<td>255</td>
</tr>
<tr>
<td>E. J.</td>
<td>529</td>
<td>415</td>
<td>382</td>
</tr>
<tr>
<td>E. C.</td>
<td>495</td>
<td>271</td>
<td>236</td>
</tr>
<tr>
<td>C. O.</td>
<td>414</td>
<td>260</td>
<td>243</td>
</tr>
<tr>
<td>T. K.</td>
<td>353</td>
<td>164</td>
<td>163</td>
</tr>
<tr>
<td>M. B.</td>
<td>326</td>
<td>236</td>
<td>—</td>
</tr>
<tr>
<td>Mean</td>
<td>586</td>
<td>326</td>
<td>248</td>
</tr>
<tr>
<td>SEM</td>
<td>61</td>
<td>41</td>
<td>21</td>
</tr>
</tbody>
</table>

* MMI was given as SSKI, 5 gtt. q. 8 h except as follows: B. R. received NaI i.v., 1 g for 2 days; E. H. received 3 ml SSKI per day; and M. C. received KI 750 mg q. 8 h.

† Unpaired *t* test for PTU vs. MMI groups. NS = *P* > 0.05.

§ For days 3–5 combined, mean T3 levels are lower in PTU group (*P* < 0.025).

The results suggest that the larger acute decreases in serum *T*<sub>3</sub> on days 1 and 2 during PTU + iodide therapy cannot be explained adequately either by inhibition of thyroid hormone secretion by iodide or by the antithyroid effect of PTU alone. The abrupt increase in the *T*<sub>3</sub>/*T*<sub>4</sub> ratio suggests that there is inhibition of peripheral deiodination of *T*<sub>3</sub>.

**Correlation of the “plateau” *T*<sub>3</sub>/*T*<sub>4</sub> ratio and dose of antithyroid agent.** If PTU inhibits peripheral *T*<sub>3</sub> production, then a dose-response relationship might be anticipated between the amount of drug given and the *T*<sub>3</sub>/*T*<sub>4</sub> ratio. As mentioned above, after the acute increase in the first 2 days, there was no significant change in these ratios in either group during days 3–5 (Fig. 4). Therefore, it seemed reasonable to use the average value of *T*<sub>3</sub>/*T*<sub>4</sub> during this period as an index of the maximum acute response of the individual patients to the antithyroid therapy. When the “plateau” *T*<sub>3</sub>/*T*<sub>4</sub> ratios were plotted for each individual against the corresponding dosage, a significant direct correlation was observed between this ratio and the dose of PTU (Fig. 5). This relationship was not apparent with MMI. A similar relationship is observed in PTU-treated patients when the percentage decrease in serum *T*<sub>3</sub> on day 1 is plotted against the dose of PTU given (*r* = 0.78, *P* < 0.01, not shown). Again, there was no such correlation in the patients receiving MMI. The results in the PTU-treated
The significant inverse correlation of \( T_3/T_4 \) ratios with serum \( T_3 \) concentrations in untreated hyperthyroidism indicates that greater increases in circulating \( T_3 \) relative to \( T_4 \) are consistently observed in this condition. This relative excess of \( T_3 \) could be due either to relatively smaller increases in the metabolic clearance of \( T_3 \) than in the metabolic clearance of \( T_4 \) or to a disproportionate increase in the production rate of this hormone. Studies by Nicoloff, Low, Dussault, and Fisher in hyperthyroid subjects suggest that the former possibility is unlikely since parallel increases in the disappearance rates of both labeled \( T_3 \) and \( T_4 \) were observed in this condition (13). The study further estimated that there was a 7-fold increase in the daily production of \( T_3 \) whereas production of \( T_4 \) was increased only 3.5-fold. The relative overproduction of \( T_3 \) in turn could be a result of either increased thyroidal \( T_3 \) secretion or increased quantities of \( T_3 \) arising from peripheral deiodination of \( T_4 \) or both. Review of recent studies by several laboratories suggests that this latter pathway is the major source of circulating \( T_3 \) in euthyroid subjects (2). If one assumes that the fraction of \( T_3 \) which is converted to \( T_4 \) per day remains constant in hyperthyroidism, then rough estimates of the relative contribution of the two pathways to the peripheral \( T_3 \) pool can be made. While the precise proportion of the peripheral \( T_3 \) pool deriving from \( T_4 \) is a matter of debate, a recent review of the literature suggests that a minimum of about two-thirds comes from this source (2). This would amount to about 80 ng/100 ml of the normal serum \( T_3 \) concentration of about 120 ng/100 ml. If peripheral \( T_3 \) production were increased 3.5-fold as is total \( T_3 \) production in hyperthyroidism (i.e., if the fractional \( T_3 \) to \( T_4 \) conversion remains constant) an increase to a serum \( T_3 \) concentration of 280 ng/100 ml would be anticipated. This amounts to 46% \((280/610)\) of the mean serum \( T_3 \) level in 19 patients examined in detail in this study. These approximations would indicate that the thyroid and the periphery contribute about equally to the \( T_3 \) pool in hyperthyroidism and that the acute inhibition of either pathway would cause similar initial decreases in serum \( T_3 \) concentrations.

The observation that iodide alone caused a rapid fall in circulating \( T_3 \) is evidence substantiating the acute inhibition of thyroid hormone secretion produced by this agent in hyperthyroid subjects. The acute inhibition of release of \(^{131}I\) from prelabeled glands was first demonstrated by Goldsmith and Eisele (14) using epithyroid counting techniques and more recently verified in studies by Wartofsky, Ransil, and Ingbar by analysis of the changes in stable and labeled serum \( T_3 \) concentrations during iodide administration (7). The latter reported a mean decrease of 74% in \( T_4 \) secretion rate. Since the half-life of \( T_3 \) is short relative to \( T_4 \), changes in the concentration of this hormone are more abrupt than changes in the latter. Since some decreases in \( T_4 \) were present during iodide therapy, peripheral \( T_4 \) production was presumably decreased as well and contributed to the overall changes observed. The effect of an agent such as MMI on \( T_3 \) levels is more difficult to analyze. It is apparent that despite the presence of effective inhibition of \( T_3 \) and \( T_4 \) synthesis, release of these hormones will continue until the preformed stores are depleted. The duration of continued \( T_3 \) and \( T_4 \) secretion will be a function of the amount of colloid and the thyroidal release rate in each individual. Thus, a heterogeneous response might be expected in any group of hyperthyroid patients. This was observed in the three patients receiving MMI (Fig. 2). A similar type of response would be anticipated in patients treated with PTU if its only mechanism of action was to inhibit thyroidal hormone production. However, in our preliminary studies, the decreases in serum \( T_3 \) during therapy with PTU alone appeared to be somewhat more acute and more consistent than those seen with MMI. This effect was different from that obtained with iodide alone in that simultaneous decreases in \( T_4 \) concentration were minimal. Consequently, the increases in \( T_3/T_4 \) ratios were greater with PTU than with either MMI or iodide. The consistency of the response pattern during PTU therapy argued against the chance occurrence of low intrathyroidal pools of \( T_3 \) relative to \( T_4 \) in the patients treated with this drug. Alternatively, it suggested that perhaps the acute decrease in serum \( T_4 \) in the absence of significant changes in serum \( T_3 \) could result from inhibition of peripheral \( T_3 \) production from \( T_4 \).

The evidence that PTU inhibits deiodination of \( T_3 \) in the experimental animal has been extensively reviewed by Morreale de Escobar and Escobar del Rey (15). Recent studies by Oppenheimer, Schwartz, and Surks have further documented that PTU administration to rats results in a decrease in the generation of labeled \( T_3 \) from labeled \( T_4 \) (10). Other studies have reported evidence of inhibition of \( T_3 \) deiodination in hyperthyroid subjects (8, 16). More recently, Nicoloff reported that PTU caused an acute inhibition of \( T_3 \) deiodination in euthyroid subjects (12). This effect was not shared by either MMI or iodide.
To our knowledge, there are no previous studies of the effect of PTU-induced inhibition of T₄ deiodination on peripheral T₃ production in either hyperthyroid or euthyroid subjects. It was apparent from the preliminary studies that the comparison of the effects of MMI and PTU on peripheral T₃ production in hyperthyroidism would be complicated by the previously discussed differences in thyroidal stores in different individuals. To overcome this problem, PTU and MMI were combined with iodide. Under these circumstances, the release of both thyroid hormones would be expected to be decreased to approximately 25% of the initial rate. Acute changes in circulating T₃ would, then, better reflect primary effects on peripheral T₃ production. The gradual decrease in circulating T₃ observed in the patients receiving MMI + iodide did not appear substantially different from the effects of iodide alone in the preliminary studies. The serum T₃ concentration appeared to plateau at about 340 ng/100 ml or 53% of the control level at about 3 days, consistent with the approximations outlined previously. The abrupt decrease of the serum T₃ to 50% of control on day 1 and to 42% of control on day 2 in the PTU group indicates that both pathways for T₃ production are inhibited. The decreasing T₃ levels in both groups was presumably a result of the iodide therapy. While there was no significant difference in the serum T₃ values between the two groups, this disappearance slope appeared shallower in the PTU-treated group as would be anticipated if T₃ deiodination were inhibited. While circulating T₃ might then tend to be higher in this group, it was primarily the significant decreases in circulating T₃ which resulted in the marked elevations in the serum T₃/T₄ ratio. Since the drugs were given in roughly the accepted potency ratio, namely, 10:1 for PTU versus MMI, it is probable that the inhibition of thyroid hormone synthesis induced by these agents was also equivalent. Because of the substantial acute inhibition of thyroidal release rate produced by iodide, small differences in the inhibition of thyroid hormone synthesis in the two groups would play little role in the observed responses.

However, the concomitant administration of iodide and antithyroid drugs requires one further comment. If inhibition of thyroid hormone formation were incomplete with these amounts of PTU and MMI, then the additional amounts of iodide could lead to the synthesis of greater amounts of hormones than would be formed in the presence of the antithyroid drugs alone. Since PTU is perhaps less than 10% as potent as MMI by weight (17), one could speculate that the T₃/T₄ ratio of newly synthesized hormones in PTU-treated patients would be greater than in MMI-treated patients, since greater restriction of iodine organification could result from the more efficient blockade by the latter drug.

The situation might be analogous to studies in rats where iodine deficiency results in a decrease in the T₃/T₄ ratio of synthesized hormones (18). However, absolute T₄ production during the apparent plateau period (days 3-5) appears to be about 50% greater during MMI therapy than during treatment with PTU. It thus seems difficult to explain the higher total T₄ production rate in MMI-treated patients as due to a greater absolute rate of thyroidal T₄ secretion resulting from more complete inhibition of organification. It is perhaps more likely, at least acutely, that the high iodide levels, in addition to inhibiting hormone release, also caused intracellular iodide concentrations sufficiently elevated to cause further inhibition of the organification process in both groups through the Wolff-Chaikoff effect (19). The similarity of the pattern of response in the PTU-treated patients, whether or not added iodide was given, would add support to these theoretical arguments.

The previous studies in animals and man, as well as the present results, point to inhibition of T₃ deiodination as the best explanation for the acute decreases in circulating T₃ resulting from PTU therapy. Further support for this interpretation is found in the dose-response relationships between the "plateau" T₃/T₄ ratio (or the T₃ decrement on day 1) and the dose of PTU administered (Fig. 5). A similar dose-response relationship over a range of 100-1,000 mg was demonstrated for PTU inhibition of T₄ deiodination in euthyroid subjects by Nicoloff (12). Previous investigations suggest that the maximum inhibition of T₄ deiodination by PTU in the rat is approximately 50% (15). If there is a similar limit in man, a plateau in this curve should eventually occur which was not evident in our studies nor in the above mentioned studies in euthyroid subjects (12).

Certain clinical implications of this study deserve further comment. If T₃ is the active form of thyroid hormone and serum concentrations are an accurate reflection of the availability of this hormone to the cells, then the acute response of patients to PTU + iodide is clearly superior to the results with MMI + iodide. Whether the chemical improvements will be paralleled by more rapid clinical improvement is currently under investigation. Unfortunately, the present series of patients was not objectively evaluated from a clinical standpoint. However, these results are sufficiently impressive to make PTU (as opposed to MMI) in combination with iodide, our drug-of-choice in the treatment of patients with thyroid storm. In patients with less severe manifestations of thyrotoxicosis, the potential benefits of more rapid decreases in T₃ levels with PTU + iodide (or MMI + iodide) must be weighed against the risks of giving two drugs simultaneously. The peripheral effects of PTU might also be therapeutically advantageous in the treatment of exogenous thyroxine in-
toxication or in postsurgical or \textsuperscript{131}I therapy-induced thyroid storm where minimal effects of any agents on thyroid hormone release are anticipated. In addition, the present studies are acute and may, therefore, have limited applicability to the effects of chronic PTU or MMI therapy on circulating T\textsubscript{3} and T\textsubscript{4} concentrations.

ACKNOWLEDGMENTS

The authors would like to express their appreciation to Ms. Darina Sipula for her careful technical assistance and to Ms. Barbara Bremner for her secretarial expertise.

This work was supported by Grant AM 14283 from NIAMDD, Grant 0-20 from the Health Research and Services Foundation of Pittsburgh, and General Clinical Research Center Grant FR 56 from the National Institutes of Health.

REFERENCES


208 J. Abild and P. R. Larsen